Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SDZ MKS 492.

J Morley1, I D Chapman, L Mazzoni

  • 1Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland.

Agents and Actions. Supplements
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

SDZ MKS 492 effectively relaxes airway smooth muscle and reduces bronchospasm in guinea pigs. This compound also demonstrates anti-inflammatory properties, suggesting potential as a single therapy for asthma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase transitions in the classical simulability of open quantum systems.

Scientific reports·2023
Same author

Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy.

Cancer immunology, immunotherapy : CII·2021
Same author

Real-time three-dimensional echocardiographic study of a cardiac hemangiosarcoma in a dog.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2020
Same author

Editorial: Loneliness in Old Age: An unaddressed Health Problem.

The journal of nutrition, health & aging·2020
Same author

Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

A comparative dermoscopic and reflectance confocal microscopy study of naevi and melanoma with negative pigment network.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same journal

Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.

Agents and actions. Supplements·1998
Same journal

Immunomodulation of Crohn's disease by interleukin-10.

Agents and actions. Supplements·1998
Same journal

Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.

Agents and actions. Supplements·1998
Same journal

Symposium new drugs for inflammatory, allergic and immunologic disease.

Agents and actions. Supplements·1998
Same journal

The complexity of the B7-CD28/CTLA-4 costimulatory pathway.

Agents and actions. Supplements·1998
Same journal

A role for inflammatory cytokines in the productive activation of antigen-specific CD4+ T-cells.

Agents and actions. Supplements·1998
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Airway smooth muscle contraction and inflammation are key features of asthma.
  • Current asthma therapies often require multiple agents to address both bronchoconstriction and inflammation.

Purpose of the Study:

  • To evaluate the bronchodilator and anti-inflammatory effects of SDZ MKS 492.
  • To assess the potential of SDZ MKS 492 as a monotherapy for asthma.

Main Methods:

  • In vitro studies on airway smooth muscle relaxation.
  • In vivo guinea-pig models of bronchospasm and airway hyperreactivity induced by various stimuli (PAF, isoprenaline, endotoxin, immune complexes).
  • Assessment of inflammatory cell infiltration (macrophages, eosinophils, neutrophils) in response to allergen challenge.

Related Experiment Videos

Main Results:

  • SDZ MKS 492 demonstrated potent relaxation of airway smooth muscle in vitro.
  • The compound inhibited or reversed bronchospasm in vivo.
  • SDZ MKS 492 attenuated airway hyperreactivity induced by various agents.
  • Inhaled SDZ MKS 492 reduced pulmonary accumulation of inflammatory cells following allergen exposure.

Conclusions:

  • SDZ MKS 492 possesses significant bronchodilator and anti-inflammatory activities.
  • The compound shows promise as a prophylactic agent against allergen-induced airway inflammation.
  • SDZ MKS 492 may offer a novel monotherapy approach for asthma management.